TLR9 and B-cell chronic lymphocytic leukemia: As multiple cell types in the LN microenvironment may affect drug resistance and proliferation of CLL cells via cytokine secretion,1 we optimized a cocktail to directly stimulate the CLL cells consisting of IL-2, IL-15, IL-21, and the TLR9 agonist CpG (Suppl.